MUNICH, 10 August 2010—Kirkland & Ellis LLP client Teva Pharmaceuticals Industries Ltd. has completed its acquisition of Ratiopharm, Germany's second largest generics producer, for EUR3.625 billion. Teva entered into an agreement to purchase Ratiopharm on 18 March 2010, and secured purchase approval from the EU Antitrust Authority on 5 August 2010.
Following the acquisition, Teva will be the number one generic company in Europe, holding the leading market position in 10 countries and ranking in the top three in seven additional countries.
A global Kirkland team advised Teva throughout the acquisition process. Corporate partners Volker Kullmann, Dr. Christian Zuleger and Dr. Björn Holland led the team out of Kirkland's Munich office. The team also included Dr. Jan Schinköth, Kai Terstiege, Dr. Daniel Wied, Markus Schmid and Nicole Schlatter (corporate); Dr. Oded Schein, Dr. Roderic Pagel and Dr. Ulf Kieker (tax); and Wolfgang Nardi, Katrin Schreiber, Christine Kaniak and Anja Wagner (finance). Corporate partner David Fox advised Teva from the New York office.
Richard Egosi, Dov P. Bergwerk and Ori Landau of Petach Tikva, Bibianne Bon of Utrecht and Nicole von Gregory of Radebeul served as Teva's in-house counsel. Teva received antitrust guidance from David Tayar and William Rooney of Willkie, Farr & Gallagher.
Kirkland & Ellis is a 1,500-attorney law firm representing global clients in complex corporate and tax, litigation and dispute resolution/arbitration, restructuring, and intellectual property and technology matters. The Firm has offices in Munich, Chicago, Hong Kong, London, Los Angeles, New York, Palo Alto, San Francisco, Shanghai and Washington, D.C.